Abstract | Diarrhoeal disease remains a major health burden worldwide. Secretory diarrhoeas are caused by certain bacterial and viral infections, inflammatory processes, drugs and genetic disorders. Fluid secretion across the intestinal epithelium in secretory diarrhoeas involves multiple ion and solute transporters, as well as activation of cyclic nucleotide and Ca 2+ signalling pathways. In many secretory diarrhoeas, activation of Cl -channels in the apical membrane of enterocytes, including the cystic fibrosis transmembrane conductance regulator and Ca
Introduction
Diarrhoeal diseases have been a major health problem throughout history. 1 In the past, diarrhoeal diseases were often fatal and disease outbreaks spread quickly, affecting large populations. Today, despite the success of interventions such as oral and intravenous rehydra tion therapy, secretory diarrhoea remains a substantial cause of mortality and morbidity worldwide, particularly in children and the elderly. In 2015, it is estimated that worldwide 577,000 children aged <5 years and 502,000 adults aged >70 years will die from diarrhoeal diseases. 2 For these vulnerable populations, the mortality risk due to diarrhoeal disease is often further increased by associ ated risk factors such as malnutrition and preexisting enteric infections. 3 In addition to the mortality risk, repeated diarrhoeal episodes are associated with long term impairment of physical and mental development, with an estimated global loss of ~1,400 years of healthy life due to disability per 100,000 population. 2, 4 The prevalence of diarrhoeal disease, as for other important global causes of childhood mortality such as pneumonia and malaria, is correlated closely with climate and economic development. The most severely affected regions include developing countries in sub Saharan Africa and South Asia. 2 The major causes of diarrhoeal diseases in developing countries are infec tious, including enterotoxinproducing bacteria, such as Vibrio cholerae and enterotoxigenic Escherichia coli; viruses, such as rotavirus; enteroinvasive bacteria, such as Shigella and Salmonella; and parasites, such as Entamoeba histolytica and Cryptosporidium parvum. 5 The most common cause of severe diarrhoea worldwide is rotavirus (28% of diarrhoeal episodes), with V. cholerae producing at least 1-2% of cases. 6 Severe diarrhoea out breaks that rapidly affect large populations are often associated with complex humanitarian emergencies such as the displacement of people into refugee camps, natural disasters such as earthquakes, and armed conflict, leading to the loss of health and sanitation infrastructure. Examples include the refugee crisis in Rwanda in 1994, the conflict in Zimbabwe in 2008, and the ea rthquake in Haiti in 2010.
Many noninfectious causes of diarrhoea are promi nent in developed countries. Diarrhoea is associated with adverse effects of drugs, particularly certain cancer and HIV therapeutics. 7, 8 Up to 28% of patients with HIV treated with protease inhibitors report more than four loose or watery stools per day. 7 Intestinal inflam matory and autoimmune conditions, such as ulcerative colitis, Crohn's disease and coeliac disease, can have a substantial diarrhoeal component. 9, 10 IBS is prevalent in developed countries; 10-20% of the adult population in the US are estimated to have IBS, of which around onethird suffer from chronic diarrhoea. 11 Severe secre tory diarrhoea is also caused by rare congenital dis orders, such as microvillus inclusion disease, familial diarrhoea syndrome and tufting enteropathy, as well as by peptidesecreting neuro endocrine tumours. [12] [13] [14] [15] However, infectious causes of diarrhoea still represent a large proportion of the disease burden in developed countries. The incidence of diarrhoea caused by rota viruses has fallen dramatically over the past 5 years with the widespread administration of the rotavirus vaccine, although the incidence of diarrhoea caused by noroviruses has increased and become the leading cause of disease outbreaks from contaminated food in the US. 16 The main bacterial causes of foodrelated diar rhoeal disease in the US are Salmonella enterica (19, 000 hospitalizations per year) and Campylobacter jejuni (8,000 hospitalizations per year), 16 and there have been annual enterohaemorrhagic E. coli outbreaks since the early 1990s.
In this Review, we describe the major pathogenic mechanisms of secretory diarrhoea, discuss currently available pharmacological therapies and therapies that are being developed, and examine the major challenges in the development of diarrhoeal therapeutics.
Mechanisms of diarrhoeal disease
Diarrhoea results from excessive secretion and/or impaired absorption of fluid and electrolytes across the intestinal epithelium ( Figure 1 ). The movement of fluid between the intestinal lumen and blood is driven by the active transport of ions, mainly Na + , Cl -, HCO 3 -and K + , and solutes, mainly glucose. Fluid absorption or secretion involves the coordinated activity of membrane transporters located on the apical (lumenfacing) and basolateral (circulationfacing) epithelial membranes. 17 The intestinal epithelium is structurally configured into long, fingerlike projections (villi) and glandular, tube like structures (crypts), with the relative villustocrypt ratio differing along the intestine. Functionally, both absorption and secretion can occur in the same epithelial cells, although secretory processes predominate in crypts and absorptive processes in villi.
Fluid absorption is driven by the active transport of Na + across the epithelium with parallel Cl -or HCO 3 -absorp tion. The electrochemical driving force for this process is the basolateral Na + /K + ATPase. In the small intestine, fluid absorption is facilitated by the sodium/hydrogen exchanger 3 (NHE3, also known as SLC9A3), sodium/ glucose cotransporter 1 (SLC5A1), and 31, 32 Intestinal fluid secretion is driven by transepithelial Cl -secretion through basolateral and apical Cl -chan nels and transporters. Cl -is transported into the cell at the basolateral membrane by a Na/K/Cl symporter (NKCC1, also known as SLC12A2), which is driven by the Na + concentration gradient produced by the Na + /K + ATPase. 33 Basolateral K + channels (KCNQ1/ KNE3 and KCNN4) provide the electrochemical driving force for apical Cl -exit across Cl -channels, 34 primarily the cyclicnucleotideactivated cystic fibro sis transmembrane conductance regulator (CFTR) and Ca 2+ activated Cl -channels (CaCCs). 33 Enteric nerves and cell surface receptors such as the calciumsensing receptor (CaSR) are thought to modulate intracellular signalling pathways and hence electrolyte absorption and secretion. 35, 36 Bacterial diarrhoeas Bacteria such as V. cholerae and enterotoxigenic E. coli secrete specific enterotoxins (for example cholera toxin and heatstable enterotoxin, respectively) that increase levels of intracellular cyclic nucleotides, resulting in activation of apical CFTR Cl -channels and hence Cl -secretion ( Figure 1b) . 37 
Viral diarrhoeas
Enteric rotavirus infection causes fluid secretion as well as structural changes in the intestinal epithelium, 46 producing an agerelated secretory diarrhoea. 47, 48 An elaborated rotaviral protein (NSP4) is thought to act as an enterotoxin causing elevation of cytoplasmic Ca 2+ concentration by binding to a membrane recep tor (integrin α 1 β 2 ), the neuropeptide galanin and/or by activation of enteric nerves (Figure 1c) . [49] [50] [51] Rotaviral NSP4 also inhibits NHE3 and SLC5A1. 52 The molecular mechanisms by which other enteric viruses such as norovirus cause diarrhoea is not known at present. 
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Congenital diarrhoeas
Congenital diarrhoeas can result from rare inher ited genetic mutations in several intestinal proteins ( Figure 1d ). The target genes in many of these familial enteropathies have been discovered with the advent of lowcost gene sequencing. Mutations in the Na + trans porter SLC5A1 underlie glucose and galactose mal absorption, and mutations in the Cl -/HCO 3 -exchanger DRA result in congenital Cl -diarrhoea. 56,57 A mutation in the guanylin receptor GUCY2C, which causes famil ial diarrhoea syndrome, results in constitutive cGMP activation with consequent CFTRmediated Cl -secre tion and NHE3 inhibition.
14 Alterations in the integrity of intestinal structure caused by mutations in proteins such as MYO5B and the epithelial cell adhesion mol ecule also result in altered signalling with putative acti vation of electrolyte secretion. 58, 59 Additional details about co ngenital diarrhoeas can be found elsewhere. 60, 61 Inflammatory diarrhoea Intestinal inflammation is seen in autoimmune diseases such as IBD and coeliac disease. Although the predomi nant feature of these diseases is chronic tissue damage secondary to inappropriate immune cell activation, several overlapping signalling pathways affect intesti nal fluid transport homeostasis. 62 Activation of epithelial inflammatory signalling pathways such as NFκB result in Ca 2+ or cyclic nucleotide signalling and stimulation of Cl -secretion or inhibition of Na + absorption ( Figure 1e ). The release of inflammatory mediators such as TNF and IL6 by activated T cells and neutrophils, which causes degranulation of mucosal mast cells and release of histamine and prostaglandins, can also stimulate Cl -secretion. 63, 64 Epithelial Na + absorption is also probably affected by inflammation, with studies showing down regulation of NHE1 (also known as SLC9A1) and NHE3 in IBD, and defective NHE3 function and regulation by adaptor proteins in an IL10deficient mouse model of colitis. [65] [66] [67] Predominantly inflammatory diarrhoea is seen in response to some bacterial pathogens, such as Clostridium difficile, which is the most common cause of nosocomial antibioticassociated diarrhoea. C. d ifficile associated diarrhoea and colitis occurs secondary to elaborated toxins that activate epithelial inflammatory signalling pathways and recruit immune cells. 68 
Current management and treatment
The acute treatment of infectious diarrhoeal diseases centres around prompt and complete amelioration of dehydration. In hospitals, particularly in developed countries, this treatment is often achieved through intravenous fluid replacement. 69 In developing coun tries and nonhospital settings oral rehydration solu tion (ORS) is the mainstay of treatment. 70 Although ORS effectively treats dehydration when administered appropriately, it does not change fluid losses, diarrhoeal output or duration of illness. Most of the current and historical therapeutics used for symptomatic treat ment are classed as antimotility agents or antisecretory agents based on their mechanism of action ( Table 1) . For diarrhoeas caused by enteric infections, various antibiotics are also used depending on the pathogenic organism. 71 Antibiotics shorten illness duration and are used particularly for dysentery (bloody diarrhoea), but selection of appropriate antibiotics requires labora tory diagnosis of the pathogenic organism, which often is not available. Although antibiotics are effective in reducing symptoms and the duration of infectious diar rhoeas, their delayed onset of action means they do not prevent immediate dehydration. Also, concerns about anti biotic resistance and the fact that they are contra indicated in specific enteric infections have prevented their r ecommendation for widespread use. 72, 73 ORS ORS is an orally ingested solution that stimulates intesti nal Na + absorption by SLC5A1 and Na + coupled amino acid transporters. The current WHOrecommended ORS is hypoosmolar (245 mOsm/l) to increase water absorp tion. 74 The widespread use of ORS over the past four decades has remarkably reduced the mortality associ ated with diarrhoeal disease by ~70%. 75 However, ORS admin istration in developing countries has stagnated since 1995, with ORS only used in 30-35% of children with diarrhoea aged <5 years. 76, 77 In the past decade, alterna tive forms of ORS have been developed. In one form, the substrate linked to Na + absorption is nonabsorbable ▶ REVIEWS starch, which is relatively resistant to digestion by pancre atic amylase and is metabolized by bacteria to shortchain fatty acids in the colon where it stimulates Na + absorp tion by NHE2 (also known as SLC9A2). 74, 78 In clinical trials, patients with cholera who receive non absorbable starch ORS have a shorter duration of diarrhoea and require less parenteral fluid support than patients who receive conventional ORS. 79 Zinc has been shown to shorten the duration of acute diarrhoea and is part of the WHOrecommended ORS. 80 The mechanism of this effect of zinc is unclear, and whether zinc deficiency plays a role has not been established. In vitro, zinc blocks Cl -secretion by inhibiting K + channels in the basolateral me mbrane and stimulating NHE3. 81, 82 Antimotility agents Drugs that inhibit intestinal motility have been used extensively to treat diarrhoea. The putative mechanism of action for antimotility drugs is increased Na + and fluid absorption as a result of slow intestinal transit. Loperamide and diphenoxylate are μopioid agonists that are widely used for mild, nonspecific diarrhoea. They are not recommended in bacterial diarrhoeas pri marily owing to the risk of paralytic ileus, and diphen oxylate also has substantial central opioid effects. 83 5hydroxytryptamine 3 antagonists such as alosetron have shown efficacy in chronic diarrhoea related to IBS; 84 however, their use has been limited by concerns of ileus and ischaemic colitis. Although loperamide is widely used and effective in mild acute diarrhoea, 85 the potential serious adverse effects of antimotility drugs together with a narrow therapeutic index has limited their r ecommendation and use, particularly for in fectious diarrhoeas.
Antisecretory agents
Reducing intestinal fluid secretion has been a rela tively underexploited area for antidiarrhoeal thera peutics. Historically, bismuth subsalicylate was shown to have antidiarrhoeal efficacy and early mechanistic studies indicated that salicylates such as aspirin inhibit e nterotoxininduced Cl -secretion and promote Na + absorption. 86 Racecadotril, an encephalinase inhibi tor, or its active metabolite thiorphan, initially showed promise as an antidiarrhoeal. Inhibition of the break down of endogenous encephalins could exert anti secretory effects through encephalinstimulated activation of epithelial μopioid receptors. Small clini cal studies initially showed efficacy in choleratoxin mediated fluid secretion; however, a large doubleblind, placebocontrolled trial showed no improvement in diarrhoeal output or duration. 87, 88 More recently, a n aturalproduc t antisecretory agent, crofelemer, has been approved for use in HIVrelated diarrhoeas based on a clinical trial showing efficacy in improving chronic diarrhoea in patients with HIV. 89 Crofelemer is a hetero geneous proanthocyanidin oligomer extracted from the bark latex of the South American tree Croton lechleri. The putative mechanism of action for crofelemer is inhib ition of Cl -channels in the apical membrane. However, in vitro studies showed crofelemer to be a weak and partial antagonist of CFTR, although a rela tively strong inhibitor of CaCCs. 90 It is unclear whether this inhibition of CaCCs underlies the efficacy of c rofelemer in HIVrelated diarrhoea.
Probiotics
Several metaanalyses and clinical studies in developed countries suggest that probiotics prevent or reduce the duration of diarrhoea. [91] [92] [93] However, these effects seem to be highly straindependent and dosedependent. Studies using specific bacterial strains have shown effects on expression and/or function of DRA, CFTR and NKCC transporters, suggesting that probiotics affect mechanisms of Cl -secretion and electroneutral absorption. [94] [95] [96] A doubleblind, placebocontrolled study in children aged 1-6 years showed that a specific probiotic (Lactobacillus reuteri) significantly reduced the incidence of acute diarrhoea, particularly in chil dren with poor nutritional status. 97 Currently, pro biotics are not routinely recommended in community settings in developing countries, although increasing evidence shows that they might be beneficial as a djunctive antidiarrhoeal therapies.
New antidiarrhoeal therapies
Most of the currently used antidiarrhoeal therapies are decades old and only in the last 5 years has there been renewed interest in development of antidiarrhoeal therapeutics, 98 with several novel drug candidates tar geting intestinal fluid transport ( Table 2) . Some of these new therapeutic candidates have emerged from greater understanding of the mechanisms of intes tinal fluid secretion and the use of highthroughput screening technology. Figure 2 depicts the molecular targets for a ntidiarrhoeal therapeutics at various stages of development.
CFTR inhibitors Activation of CFTR Cl
-channels in the small intestine and colon occurs in secretory diarrhoeas caused by bac terial enterotoxins secreted in cholera and Traveller's diarrhoea. 99 Intestinal Cl -and fluid secretion are absent in CFTRknockout mice and in patients with cystic fibro sis, 100, 101 and the use of CFTR inhibitors blocks colonic Cl -transport in human tissue. 99 Highthroughput screen ing has revealed three chemical classes of smallmolecule CFTR inhibitors. The thiazolidinone CFTR inh 172 ( Figure 3 ) inhibits CFTR by binding at or near Arg347 and stabilizes the channel in its closed state. 102 Studies in mouse models of cholera and intestinal fluid secretion induced by heatstable toxin have demonstrated efficacy of CFTR inh 172. 99, 103 Another class of CFTR inhibitors, which probably interfere with ATP gating, are the PPQ/ BPO compounds; 104, 105 the most potent of these com pounds, (R)BPO27, inhibits CFTR Cl -conductance with IC 50 ~4 nM and has shown efficacy in models of polycystic kidney disease, 104 but has not yet been tested in models of diarrhoea.
Glycine hydrazides such as GlyH101 are another class of CFTR inhibitors that bind to the CFTR pore on its extracellular surface as demonstrated by patch clamp, molecular modelling and efficacy of a m embraneimpermeant polyethylene glycolhydrazide conjugate. 106 The GlyH101 analogue iOWH032 has completed a safety clinical trial, 107 although a planned phase II trial (NCT02111304) has been terminated before patient enrolment. iOWH032 is unlikely to be effective because it is a weak CFTR inhibitor and can undergo rapid convective washout in the intestine. 108 To address the potency and washout limitations, non absorbable macromolecular conjugates have been syn thesized containing a malonic acid hydrazide (MalH) moiety that inhibits CFTR. One such conjugate, MalH lectin, inhibited CFTR with an IC 50 down to 50 nM, remained bound to CFTR for >6 h, and reduced mor tality in a neonatal mouse model of cholera. 109 The high potency of the MalHlectin conjugate and its resistance to washout is possibly due to trapping in the glycocalyx on enterocytes. Multivalent MalHpolyethylene glycol conjugates have also been synthesized and shown to be CFTR inhibitiors with nanomolar potency, 110 greater chemical stability and lower cost than lectincontaining CFTR inhibitor conjugates.
CaCC inhibitors
CaCCs provide a second route for Cl -secretion by enterocytes and might also be involved in enterotoxin mediated secretory diarrhoeas by crosstalk in signal ling mechanisms. CaCCs probably represent the primary pathway for apical membrane Cl -secretion in rotaviral and perhaps other viral diarrhoeas, 48 as well as in secre tory diarrhoeas induced by some HIV protease inhib itors 54 and chemotherapeutics. 55 The molecular identity of the major CaCC(s) in enterocytes remains unclear. The CaCC anoctamin1 is expressed in interstitial cells of Cajal and has an important role in intestinal motil ity, 111 but its role in Cl -conductance in enterocytes remains uncertain. 112 Smallmolecule and naturalproduct CaCC inhibitors have been identified. A phenotypebased screen in HT29 cells identified several smallmolecule CaCC inhibitors, the most potent being the 3acyl2aminothiophen e CaCC inh A01. 113 CaCC inh A01 prevented watery diar rhoea in a neonatal mouse model of rotavirus. 114 Screening of natural products to find potential CaCC inhibitors identified tannic acid, which motivated the discovery that polyphenolic gallotannins strongly inhibit CaCCs. Remarkably, oral administration of an alcohol free red wine extract prevented rotaviral diarrhoea in neonatal mice, without effect on the rotaviral infection. 114 The red wine extract did not inhibit CFTR or prevent choleratoxininduced intestinal fluid secretion. In another naturalproduct study, diarrhoea remedies from sources around the world were screened for inhibition of Cl -channels. A commonly used Thai herbal remedy fully inhibited both CFTR and CaCC Cl -conductance in vitro, and was efficacious in mouse models of cholera and rotaviral diarrhoea. 115 Natural products represent inexpensive and readily available potential therapies for serious secretory diarrhoeas.
NKCC1 inhibitors
The electroneutral NKCC1 transporter is the major pathway for Cl -entry into enterocytes from the blood side and is therefore an attractive target for development of inhibitors that are predicted to block both CFTR mediated and CaCCmediated secretory diarrhoeas. NKCC inhibitors such as bumetanide are approved for use as diuretics, as the kidney expresses the NKCC2 isoform. Although novel NKCC1 inhibitors are emerging from screening efforts, challenges in their development for diarrhoeal therapy include obtaining high selectivity over NKCC2 (to prevent diuretic action) or confining their action to the intestine, and preventing potential offtarget effects such as hearing impairment seen in NKCC1knockout mice. 116 
CaSR agonists
The CaSR is a Gproteincoupled receptor expressed throughout the small intestine and colon. 117 In the small intestine the CaSR is expressed on the basolateral mem branes of crypt and villus epithelial cells and on the apical surface of villus cells, 117 while in the colon it is present on the apical and basolateral membrane of crypt cells and on cells of the enteric nervous system and some entero endocrine cells. Figure 2 | Potential therapies for secretory diarrhoeas at various stages of development and their molecular targets. Various molecular targets including intestinal ion channels and transporters, regulatory proteins and cell surface receptors are found on epithelial cells lining the intestine, enteric nerves and enterocytes. Novel therapeutics targeting these molecules are in the development pipeline. Abbreviations: AF, antisecretory factor; BPO, benzopyrimido-pyrrolo-oxazinedione; CaCC, calcium-activated chloride channel; CaSR, calcium-sensing receptor; CFTR, cystic fibrosis transmembrane conductance regulator; EC, enterochromaffin; LPA, lysophosphatidic acid; LPAR2, LPA receptor 2; NHE, sodium/hydrogen exchanger; NKCC, Na/K/Cl symporter; PPQ, pyrimido-pyrrolo-quinoxalinedione.
breakdown of cyclic nucleotides by phosphodiesterase activation 35 and regulation of tight junction assembly. to be an exaggeration of the NHE3 inhibition that occurs physiologically early in the postprandial state. 122 NHE3 activity in enterocytes is inhibited following acute eleva tions in cAMP, cGMP or Ca 2+ concentrations, as pro duced by bacterial enterotoxins, ionophores or humoral agonists including 5hydroxytryptamine and carba chol. 28, 123, 124 These mechanisms probably apply in human secretory diarrhoeas. NHE3 activity is reduced in con genital Na + diarrhoea as seen in intestinal biopsies, 125 with mutations in the transport domain of NHE3 account ing for this autosomal recessive condition (A. Janecke et al., unpublished data). Human enteroids generated from proximal small intestine of healthy individuals show NHE3 activity under basal conditions, which is acutely stimulated by dexamethasone and inhibit ed by cAMP, cGMP, Ca 2+ , bacterial enterotoxins and rotaviral infection. 126 A peptide that mimics part of the NHE3 Cterminal domain and prevents NHE3 inhibition by cAMP, Ca 2+ and cholera toxin has potential utility as a proabsorptive therapeutic.
Antisecretory factor
A secreted, 41 kilodalton protein named antisecretory factor released mainly from the pituitary gland 127 has been shown in rodent models to prevent intestinal fluid secretion induced by cholera toxin, heatstable toxin, C. difficile toxin A, Campylobacter toxin and prosta glandins. 128 The active component of antisecretory factor consists of seven amino acids in its Nterminus. The antisecretory factor16 peptide, consisting of the active Nterminal domain of the antisecretory factor, also blocks intestinal fluid secretion. The exact mechanism of action for antisecretory factor is unclear, but the anti secretory effect of antisecretory factor16 was abolished by vagot omy, suggesting its action is on nerves and perhaps on capillary permeability. A modified eggyolk product enriched with antisecretory factor (Salovum®, ASFaktor AB, Sweden) reduced the duration of acute and prolonged (>7 days) diarrhoea in a randomized, placebocontrolled trial in children aged 7-60 months. 129 Further clinical and mechanistic studies are needed for this promising drug.
Lysophosphatidic acid
Lysophosphatidic acid is a naturally occurring phospho lipid present in many foods. Several studies have sug gested that interaction of lysophosphatidic acid with its intestinal receptor (lysophosphatidic acid receptor 2) results in the formation of a macromolecular complex that modulates CFTR activity. Lysophosphatidic acid receptor agonists prevent enterotoxinmediated fluid secretion in rodents, suggesting that LPAbased nutri tional supplements could be used as adjunct therapy in diarrhoea. 130 Lysophosphatidic acid also stimulates NHE3 in the small intestine through lysophosphatidic acid receptor 5 on Na + absorptive cells.
131
Other potential therapies Several other potential antidiarrhoeal therapeutics with specific indications are currently in phase II or phase III clinical trials (Figure 2 ). Eluxadoline is a mixed μopioid and δopioid inhibitor with antimotility and analgesic properties developed primarily for diarrhoea predomina nt IBS. Results from phase II trials showed some clinical improvement in stool consistency and abdominal pain, and little rebound constipation.
132
Another compound aimed at diarrhoeapredominant IBS showing efficacy in phase II trials is LX1033, an inhibitor of tryptophan hydroxylase that affects intes tinal motility by inhibition of 5hydroxytryptamine synthesis. 133 A semisynthetic bile acid analogue, obeti cholic acid, which activates the nuclear bile acid recep tor (farnesoid X receptor), relieves symptoms in patients with bile acid diarrhoea, which has been suggested to contribute to diarrhoea in some patients with IBS. 134 The action of obeticholic acid is thought to involve a feed back mechanism with an increase in the bile acid recep tor, which results in increased intestinal production of fibroblast growth factor 19 and uptake into the portal system, thus reducing hepatic bile acid synthesis and intralumina l bile salt concentration.
Conclusions and future challenges
Although diarrhoeal diseases remain a major global health challenge, there has been a remarkable lack of effective new therapeutics. Part of the reason for the lack of progress is that global and regional health policy has rightly focused on approaches targeted at preven tion, such as vaccines, improved sanitation, and better health delivery including the use of ORS. As described herein, there is now an emerging pipeline of potential anti diarrhoeal agents. In developing countries where diarrhoeas are primarily caused by infection, these new agents might be useful as adjuncts or additives to ORS, reducing diarrhoeal output and hence protecting against severe dehydration particularly in the early stages of disease, and secondarily promoting ORS usage. In complex medical emergencies, where availability of rehy dration fluids might be limited, such therapeutics could provide lifesaving alleviation of fluid loss. To be benefi cial in developing countries the ideal therapeutic should have a wide therapeutic index, be stable in harsh envi ronments and be extremely lowcost. Major challenges in moving forward include funding, logistics and design of informative clinical trials. The development of drugs that can be used safely in children and the elderly, where the disease burden is greatest, poses additional challenges in terms of drug adverse effects and patient recruitment for clinical trials. For indications such as diarrhoeas related to chronic inflammatory diseases, IBD or druginduced diarrhoeas, the development pathway for antisecretory or proabsorptive compounds is clearer, as in the case of crofelemer. Progress towards new antisecretory agents has been accelerated with the elucidation of new regulatory pathways in intestinal fluid transport, raised awareness of naturalproduct remedies, and emergence of new tools such as ionsensitive fluorescent proteins and human enteroid models for drug screening. The next and more challenging process will be translating these discoveries into safe, lowcost therapies to reduce the global health and economic burden of diarrhoeal diseases. 
